TABLE 1.

Pharmacokinetic parameters of ABT-773 and M-1 as determined by LC-MS after the administration of ABT-773 alone and with concomitant administration of ranitidine or sucralfate

AnalyteTreatmentaMean ± SD
Cmax (ng/ml)Tmax (h)AUC0-last (ng · h/ml)AUC0-∞ (ng · h/ml)t1/2 (h)
ABT-773A318 ± 1611.79 ± 0.501596 ± 8761662 ± 9075.66 ± 0.77
B236 ± 1052.04 ± 0.501242 ± 4241310 ± 4326.25 ± 1.08
C319 ± 1801.92 ± 0.631680 ± 10301748 ± 10595.76 ± 0.81
M-1A112 ± 43.11.79 ± 0.54401 ± 179429 ± 1864.12 ± 1.61
B84.4 ± 46.61.88 ± 0.31301 ± 124328 ± 1293.85 ± 1.30
C118 ± 55.41.92 ± 0.63417 ± 208444 ± 2144.41 ± 1.72
  • a Treatment A, ABT-773 alone; treatment B, ABT-773 plus ranitidine; treatment C, ABT-773 plus sucralfate.